Amryt transforms itself with takeover of US pharma firm to develop key drugs

Amryt transforms itself with takeover of US pharma firm to develop key drugs
Dr Joe Wiley, chief executive of Amryt, says treatments for rare diseases are a growing market

The chance to advance medicines for rare conditions such as EB, or butterfly skin, spurred the company on to make the acquisition

Just over four years ago, Dr Joe Wiley set about building Amryt into a world leader in developing rare and orphan disease drugs. It came about via an unusual route: a reverse takeover of a tiny Dublin-based oil and gas exploration company called Fastnet that was looking for other opportunities. Fast forward four years and Amryt has just finalised a transformational takeover of an American drug company called Aegerion that will catapult it into the...

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post